PubMed Health⌕ Search

PubMed · 7483728

Current problems in primary biliary cirrhosis.

Abstract

Despite the many advances made in the field of PBC, the central questions of this enigmatic disease remain unanswered. The pathogenesis is uncertain and there is no effective therapy. Of the various aetiologies proposed for the disease none has really withstood the test of time: if the disease were truly auto-immune, it might be anticipated that there would be a clear-cut response to cortico-steroid therapy: although such treatment has a slight effect on improving liver chemistry, compared with other auto-immune diseases such as auto-immune chronic active hepatitis. Steroids are relatively ineffective. An infectious aetiology has been suggested but no organism has been reliably isolated or implicated in the disease. Attempts at treatment have been largely hindered by the long natural history and the uncertainty as to choosing appropriate endpoints for studies. Perhaps the most intriguing observation has been the association with the anti-mitochondrial antibodies. While the antigens have been identified, these are ubiquitous enzymes locate within the mitochondrion. How antibodies to such antigens are involved in the pathogenesis remains uncertain although our recent demonstrations that some antigens may be present on the surface of biliary epithelial cells may answer the question. However, further work may be required to confirm these findings and then to determine the reasons why there is such abnormal antigen expression in the disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Neuberger. 1993. Current problems in primary biliary cirrhosis.. https://pubmed.ncbi.nlm.nih.gov/7483728/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗